Skip to main content
Equibles

4886 · ASKA Pharmaceutical Holdings CO., Ltd. · Financials

Use 4886 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4886.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,190 JPY +41 (+1.91%) At close · Nov 12
Rebalance outlook locked
Market Cap
62.30B JPY
Shares
28.45M
Volume · Nov 12 78.7K Avg daily vol (3M) 67.37K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
71.13B +10.9%
FY2026 Revenue FY2022–FY2026
Net Income
5.42B +6.3%
FY2026 Net Income FY2022–FY2026
Gross Margin
48.01% -0.8pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
8.2% -0.1pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
6.3B +153.6%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 71.13B 64.14B 62.84B 60.46B 56.61B
JPY 36.98B 32.8B 32.18B 31.88B 30.26B
JPY 34.15B 31.34B 30.66B 28.58B 26.35B
JPY 5.83B 5.33B 6.5B 5.11B 4.8B
JPY 6.99B 6.19B 9.86B 5.36B 6.16B
JPY 1.37B 1.09B 2.32B 1.12B 1.87B
JPY 5.42B 5.1B 7.55B 4.24B 4.29B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 4.53B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.